raloxifene

Raloxifene hydrochloride (LY156758 hydrochloride) is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Raloxifene (LY139481) is a selective estrogen receptor modulator that exhibits both estrogen agonist and antagonist activities at certain sites, with antiviral activity against viruses like Ebola, influenza, and HCV, useful for studying viral infections.

4'-Raloxifene-β-D-glucopyranoside is a metabolite of Raloxifene. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist.

6-Raloxifene-β-D-glucopyranoside is a benzothiophene glucuronidated at the 6' position. It is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss, resorption, and lowering lipid

7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is an LRH-1 antagonist with an IC50 of 3.1 μM.

Raloxifene 4'-glucuronide, a primary metabolite of Raloxifene.

Raloxifene 6,4'-Bis-β-D-glucuronide, a metabolite of Raloxifene, acts as a selective antagonist of the estrogen receptor used for osteoporosis prevention.

Raloxifene 6-glucuronide, a primary metabolite of Raloxifene, is mediated predominantly by UGT1A1 and UGT1A8.

4-tert-Butyldimethylsilyl-6-hydroxy Raloxifene is a compound resulting from the reaction of Raloxifene with tertbutyldimethylsilyl chloride.

Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate) is a derivative of Raloxifene 4'-glucuronide, engineered to mimic the structure and function of the parent compound.

Raloxifene Bismethyl Ether hydrochloride, a metabolite of Raloxifene, is an estrogen receptor inactive compound with both hydroxyl groups absent.

Raloxifene Bismethyl Ether, a Raloxifene metabolite, is an estrogen receptor inactive compound that lacks both hydroxyl groups.

Raloxifene N-Oxide is an oxidative degradation product of Raloxifene.

Compound 7, or Raloxifene 6-Monomethyl Ether, is a derivative of Raloxifene that effectively inhibits estrogen receptor α. It also displays the inhibitory effects on MCF-7 cells, with an IC50 of 250 nM and a pIC50 of 6.6.

Raloxifene 4-Monomethyl Ether (Compound 37) is a Raloxifene derivative that inhibits estrogen receptor α, suppressing MCF-7 cell activity with an IC50 of 1 μM and a pIC50 of 6.

Raloxifene dimethyl ester hydrochloride (analog of Raloxifene)

Desketoraloxifene is a selective estrogen receptor modulator, inhibiting mammalian PLD (PLD1 and PLD2).

LY88074 is a raloxifene analog in which the basic side chain has been removed. LY88074 is an agonist of ERβ (EC50 = 232 nM).This compound stimulates uterine cell proliferation.

LY117018 shows antiproliferative effects on breast cancer cell lines. LY117018 is a Raloxifene analog and is a selective estrogen receptor modulator.

Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator (SERM) with a fixed ring structure similar to raloxifene. It exhibits potent antiestrogenic effects on breast cancer and endometrium with minimal side effects and provides beneficial estrogenic effects on bone health and lipid profile.

LY117018 TFA, an analog of Raloxifene, functions as a selective estrogen receptor modulator and demonstrates antiproliferative effects on breast cancer cell lines [1] [2] [3].

Silybin B (Silibinin B) is an effective inhibitor of raloxifene 4 '- and 6-glucosalylation, an effective anti-fibrinogenic and anti-oligomeric component of Silymarin, with free radical scavenging activity of 1, 1-diphenyl-2-pyridinyl hydrazine (DPPH), and a protective effect against cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. Silybin B can inhibit the growth of human chronic myeloid leukemia K562 cells and induce apoptosis.